Literature DB >> 7193020

Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 1: Antimuscarinic and spasmolytic effects.

J M Zwagemakers, V Claassen.   

Abstract

1-Cyclohexyl-4-[ethyl(p-methoxy-alpha-methylphenethyl)amino]-1-butanone hydrochloride (secoverine hydrochloride) is a neurotropic spasmolytic agent with specific antimuscarinic properties. On the basis of the results obtained, the possibility exists that secoverine acts only a sub-group of muscarinic receptors. 1. In in vitro experiments the competitive antagonism of secoverine against muscarinomimetics was demonstrated on guinea pig ileum, rat jejunum and calif trachea smooth muscle. On the basis of the mean difference of the pA2 values and in accordance with the relative activity as determined by 4-point assays, it may be concluded that secoverine is about 0.6 times as active as atropine. 2. In in vivo experiments the antimuscarinic activity of secoverine on ileum of guinea pig, rat and dog proved to be 0.6 times of atropine, by both parenteral and intraduodenal routes of administration. It was shown that the action of secoverine was reversible, of quick onset and of long duration. 3. By contrast, secoverine had only marginal effects on the sphincter and ciliary muscle of the eye, almost no effect on cholinergically-induced salivation and lacrimation, gastric acid production, urinary bladder function, gastric emptying or normal peristalsis. 4. The central anticholinergic activity was more in accordance with the activity found in the spasmolytic tests. 5. Apart from the neurotropic action, secoverine has also a good musculotropic activity as was found in in vivo and in vitro experiments. The activity varied from 3.3--13.3 times that of papaverine in the different organs investigated. The musculotropic activity is not caused by a specific, verapamil-like, calcium antagonism. 6. Secoverine has no nicotinolytic or antihistaminic activity, a moderate antisterotonic activity, an inhibiting effect on the noradrenaline uptake mechanism of the vas deferens and a marked local anaesthetic activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7193020

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat.

Authors:  B R Stewart; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2 and ileal M3 receptors.

Authors:  M H Richards
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

3.  Enhancement by secoverine and physostigmine of retention of passive avoidance response in mice.

Authors:  A J Gower
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Effect of secoverine on colonic myoelectric activity in diverticular disease of the colon.

Authors:  M Suchowiecky; D D Clarke; M Bhasker; R J Perry; W J Snape
Journal:  Dig Dis Sci       Date:  1987-08       Impact factor: 3.199

5.  Determination of the muscarinic receptor subtype mediating vasodilatation.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

6.  The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome.

Authors:  M Ehsanullah; D A Lee; T Williams; P Pollard; B Gazzard
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

7.  Interaction of some muscarinic agonists and antagonists at the prejunctional muscarinic receptor in the rabbit ear artery preparation.

Authors:  L K Choo; F Mitchelson; Y M Vong
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.